Results 41 to 50 of about 2,795 (144)
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou +6 more
wiley +1 more source
ERJ Open Research, 2019 Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator gene (CFTR) that result in diminished quantity and/or function of the CFTR anion channel.
Jennifer L. Taylor-Cousar +11 more
doaj +1 more source
Journal of Extracellular Biology, Volume 5, Issue 8, August 2026.ABSTRACT Chronic antibiotic‐resistant cystic fibrosis (CF) lung infections are the leading cause of death in adults with CF. Despite advances in highly effective modulator therapies, microbial communities persist in the CF lung. The pathogenesis of CF airway infections can be exacerbated by pathogens such as Pseudomonas aeruginosa, which communicates ...
Lily A. Charpentier +10 more
wiley +1 more source
Thoracic Research and PracticeThe objective of the study was to assess and compare the efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treatment with TEZ/IVA treatment in individuals diagnosed with cystic fibrosis (CF) and carrying the F508del allele.
Kainat Hussain +3 more
doaj +1 more source
MedComm, Volume 7, Issue 8, August 2026.Obstructive sleep apnea (OSA) is characterized by recurrent upper‐airway collapse, which generates key nocturnal stressors including intermittent hypoxia, sleep fragmentation, intrathoracic pressure stress, and sympathetic activation. These physiological disturbances converge on shared biological mechanisms, including oxidative stress, inflammation ...
Nhi Ho Thi Thuy +8 more
wiley +1 more source
Clinical Case Reports, 2021 Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute ...
Donatello Salvatore +4 more
doaj +1 more source
Pediatric Pulmonology, Volume 61, Issue 8, August 2026.ABSTRACT Background People with cystic fibrosis (CF) are at increased risk of fat‐soluble vitamin (A, D, E, and K) deficiencies secondary to exocrine pancreatic insufficiency (EPI). Estimation of vitamin K deficiency in routine clinical practice is challenging, and no uniform consensus exists due to lack of an accurate clinical test for the evaluation ...
Senthilkumar Sankararaman +7 more
wiley +1 more source
Internal Medicine Journal, Volume 56, Issue 8, Page 1356-1360, August 2026.Abstract Background Greater insight into the effects of cystic fibrosis (CF) transmembrane modulators such as elexacaftor‐tezacaftor‐ivacaftor (ETI) on glucose metabolism can support a more dynamic and individualised approach to CF‐related dysglycaemia.
Yi W. Chen +3 more
wiley +1 more source
JGH Open, Volume 10, Issue 7, July 2026.ABSTRACT Background Cystic fibrosis (CF) is an autosomal recessive disorder that has been associated with increased risk of colorectal neoplasia and cancer (CRC). Current consensus statements recommend early screening and surveillance colonoscopies for CRC in CF, though high‐quality data supporting this remains lacking.
Dazhong Huang +8 more
wiley +1 more source
Pregnancy, Volume 2, Issue 4, July 2026.Abstract Background The consequences of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein dysfunction or absence begin during fetal development, with pancreatic, intestinal, hepatobiliary, and reproductive manifestations evident at birth.
Hiba J. Mustafa +15 more
wiley +1 more source